Half-Year Review of Inventiva’s Liquidity Contract with Kepler
Cheuvreux
Daix (France), Long Island City (New
York, United States),
January 30,
2023 – Inventiva
(Euronext Paris and Nasdaq: IVA) (the “Company”),
a clinical-stage biopharmaceutical company focused on the
development of oral small molecule therapies for the treatment of
patients with non-alcoholic steatohepatitis (NASH) and other
diseases with significant unmet medical needs, today announced the
half-year report of its liquidity contract with Kepler
Cheuvreux.Under the liquidity contract granted to Kepler Cheuvreux
by Inventiva, the following resources were available in the
liquidity account as of December 31, 2022:
- Cash: € 282,479.85
- Number of shares: 113,003
- Number of executions on buy side on
semester: 541
- Number of executions on sell side
on semester: 491
- Traded volume on buy side on semester: 116,853 shares for €
574,407.24
- Traded volume on sell side on
semester: 103,989 shares for € 540,127.34
At the last half-year report as of June 30,
2022, the following resources were available in the liquidity
account:
- Cash: € 316,759.75
- Number of shares: 100,139
- Number of executions on buy side on
semester: 993
- Number of executions on sell side
on semester: 636
- Traded volume on buy side on
semester: 152,845 shares for € 1,470,441.72
- Traded volume on sell side on
semester: 98,168 shares for € 1,025,659.18
When the contract was initially implemented, the
following resources were included in the liquidity account:
- Cash: € 163,510.42
- Number of shares: 34,063
|
Buy Side |
|
Sell Side |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
Total |
1534 |
269698 |
2 044 848,96 |
|
1127 |
202157 |
1 565 786,52 |
03/01/2022 |
8 |
1000 |
11 800,00 |
|
12 |
2471 |
29 553,16 |
04/01/2022 |
33 |
4501 |
53 336,85 |
|
11 |
2000 |
24 160,00 |
05/01/2022 |
20 |
1950 |
22 542,00 |
|
2 |
500 |
5 850,00 |
06/01/2022 |
3 |
49 |
563,50 |
|
- |
- |
- |
07/01/2022 |
38 |
3187 |
36 013,10 |
|
- |
- |
- |
10/01/2022 |
30 |
3999 |
43 709,07 |
|
- |
- |
- |
11/01/2022 |
7 |
1000 |
10 680,00 |
|
13 |
2060 |
22 309,80 |
12/01/2022 |
12 |
2000 |
22 160,00 |
|
9 |
3440 |
38 872,00 |
13/01/2022 |
9 |
500 |
5 480,00 |
|
- |
- |
- |
14/01/2022 |
5 |
1500 |
16 380,00 |
|
21 |
1614 |
17 931,54 |
17/01/2022 |
2 |
1000 |
10 980,00 |
|
7 |
639 |
7 099,29 |
19/01/2022 |
3 |
222 |
2 442,00 |
|
- |
- |
- |
20/01/2022 |
1 |
1 |
11,20 |
|
19 |
3008 |
33 689,60 |
21/01/2022 |
8 |
1234 |
13 771,44 |
|
6 |
203 |
2 285,78 |
24/01/2022 |
30 |
5265 |
57 072,60 |
|
- |
- |
- |
25/01/2022 |
1 |
1 |
10,54 |
|
- |
- |
- |
26/01/2022 |
- |
- |
- |
|
8 |
1500 |
16 125,00 |
27/01/2022 |
3 |
1000 |
10 680,00 |
|
5 |
500 |
5 400,00 |
28/01/2022 |
8 |
1319 |
14 179,25 |
|
17 |
2537 |
27 627,93 |
31/01/2022 |
15 |
1932 |
20 614,44 |
|
9 |
2000 |
21 560,00 |
01/02/2022 |
- |
- |
- |
|
31 |
5500 |
61 105,00 |
02/02/2022 |
- |
- |
- |
|
8 |
1000 |
11 800,00 |
03/02/2022 |
10 |
2000 |
22 720,00 |
|
11 |
827 |
9 436,07 |
04/02/2022 |
4 |
501 |
5 691,36 |
|
24 |
1565 |
17 966,20 |
07/02/2022 |
3 |
500 |
5 750,00 |
|
9 |
2000 |
23 340,00 |
08/02/2022 |
3 |
501 |
5 811,60 |
|
17 |
3000 |
35 580,00 |
09/02/2022 |
7 |
1501 |
17 666,77 |
|
16 |
1500 |
17 880,00 |
10/02/2022 |
- |
- |
- |
|
1 |
50 |
598,00 |
11/02/2022 |
8 |
542 |
6 449,80 |
|
4 |
950 |
11 381,00 |
14/02/2022 |
27 |
4852 |
56 380,24 |
|
- |
- |
- |
15/02/2022 |
4 |
500 |
5 530,00 |
|
- |
- |
- |
16/02/2022 |
4 |
500 |
5 550,00 |
|
3 |
501 |
5 641,26 |
17/02/2022 |
25 |
2501 |
27 511,00 |
|
1 |
422 |
4 709,52 |
18/02/2022 |
4 |
1000 |
10 860,00 |
|
12 |
2185 |
23 947,60 |
21/02/2022 |
31 |
3546 |
38 119,50 |
|
- |
- |
- |
22/02/2022 |
23 |
3648 |
37 428,48 |
|
5 |
755 |
7 776,50 |
23/02/2022 |
- |
- |
- |
|
40 |
4245 |
44 827,20 |
24/02/2022 |
31 |
5306 |
53 272,24 |
|
2 |
155 |
1 612,00 |
|
Buy Side |
|
Sell Side |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
Total |
1534 |
269698 |
2 044 848,96 |
|
1127 |
202157 |
1 565 786,52 |
25/02/2022 |
- |
- |
- |
|
36 |
4345 |
45 622,50 |
28/02/2022 |
4 |
500 |
5 250,00 |
|
7 |
3500 |
38 360,00 |
01/03/2022 |
6 |
1749 |
19 169,04 |
|
10 |
2109 |
23 768,43 |
02/03/2022 |
16 |
2548 |
27 696,76 |
|
- |
- |
- |
03/03/2022 |
11 |
1842 |
19 506,78 |
|
- |
- |
- |
04/03/2022 |
16 |
2058 |
21 403,20 |
|
- |
- |
- |
07/03/2022 |
27 |
5430 |
52 671,00 |
|
10 |
2500 |
24 750,00 |
08/03/2022 |
5 |
1501 |
14 964,97 |
|
8 |
2501 |
25 760,30 |
09/03/2022 |
6 |
1000 |
9 950,00 |
|
2 |
548 |
5 540,28 |
10/03/2022 |
- |
- |
- |
|
3 |
500 |
5 050,00 |
11/03/2022 |
6 |
1000 |
9 950,00 |
|
- |
- |
- |
14/03/2022 |
4 |
1500 |
15 060,00 |
|
6 |
500 |
5 050,00 |
15/03/2022 |
17 |
2500 |
24 575,00 |
|
1 |
23 |
227,70 |
16/03/2022 |
6 |
500 |
5 000,00 |
|
11 |
1977 |
19 849,08 |
17/03/2022 |
8 |
1000 |
10 100,00 |
|
7 |
1452 |
14 955,60 |
18/03/2022 |
4 |
500 |
5 050,00 |
|
1 |
94 |
958,80 |
21/03/2022 |
4 |
1000 |
10 000,00 |
|
2 |
407 |
4 192,10 |
22/03/2022 |
5 |
251 |
2 530,08 |
|
14 |
1999 |
20 409,79 |
23/03/2022 |
3 |
500 |
5 150,00 |
|
2 |
500 |
5 200,00 |
24/03/2022 |
6 |
500 |
5 100,00 |
|
- |
- |
- |
25/03/2022 |
12 |
926 |
9 454,46 |
|
2 |
260 |
2 678,00 |
28/03/2022 |
4 |
500 |
5 095,00 |
|
4 |
548 |
5 638,92 |
29/03/2022 |
2 |
501 |
5 110,20 |
|
14 |
2457 |
25 307,10 |
30/03/2022 |
3 |
311 |
3 234,40 |
|
3 |
495 |
5 148,00 |
31/03/2022 |
11 |
542 |
5 631,38 |
|
- |
- |
- |
01/04/2022 |
8 |
1234 |
12 685,52 |
|
- |
- |
- |
04/04/2022 |
5 |
598 |
6 099,60 |
|
6 |
1000 |
10 320,00 |
05/04/2022 |
1 |
228 |
2 325,60 |
|
2 |
500 |
5 150,00 |
06/04/2022 |
1 |
137 |
1 397,40 |
|
1 |
6 |
61,80 |
07/04/2022 |
3 |
500 |
5 100,00 |
|
3 |
170 |
1 751,00 |
08/04/2022 |
5 |
473 |
4 777,30 |
|
2 |
2 |
20,40 |
11/04/2022 |
1 |
485 |
4 898,50 |
|
8 |
998 |
10 179,60 |
12/04/2022 |
10 |
1000 |
10 150,00 |
|
3 |
867 |
8 886,75 |
13/04/2022 |
17 |
1599 |
15 910,05 |
|
- |
- |
- |
14/04/2022 |
17 |
1500 |
14 655,00 |
|
1 |
100 |
990,00 |
19/04/2022 |
- |
- |
- |
|
2 |
500 |
4 900,00 |
20/04/2022 |
1 |
1 |
9,70 |
|
20 |
1500 |
14 850,00 |
21/04/2022 |
2 |
6 |
59,28 |
|
6 |
500 |
5 000,00 |
|
Buy Side |
|
Sell Side |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
Total |
1534 |
269698 |
2 044 848,96 |
|
1127 |
202157 |
1 565 786,52 |
22/04/2022 |
5 |
495 |
4 900,50 |
|
- |
- |
- |
25/04/2022 |
20 |
1782 |
17 231,94 |
|
1 |
7 |
69,30 |
26/04/2022 |
11 |
2401 |
22 425,34 |
|
- |
- |
- |
27/04/2022 |
6 |
2005 |
17 984,85 |
|
- |
- |
- |
28/04/2022 |
1 |
20 |
180,00 |
|
8 |
1250 |
11 400,00 |
29/04/2022 |
- |
- |
- |
|
7 |
2000 |
18 500,00 |
02/05/2022 |
4 |
500 |
4 600,00 |
|
11 |
550 |
5 120,50 |
03/05/2022 |
3 |
150 |
1 392,00 |
|
- |
- |
- |
05/05/2022 |
2 |
102 |
938,40 |
|
1 |
450 |
4 230,00 |
06/05/2022 |
6 |
898 |
8 315,48 |
|
- |
- |
- |
09/05/2022 |
14 |
1980 |
17 919,00 |
|
- |
- |
- |
11/05/2022 |
10 |
2544 |
22 387,20 |
|
9 |
1316 |
11 962,44 |
12/05/2022 |
10 |
1207 |
10 452,62 |
|
- |
- |
- |
13/05/2022 |
6 |
678 |
5 810,46 |
|
2 |
802 |
7 009,48 |
16/05/2022 |
8 |
1291 |
10 973,50 |
|
- |
- |
- |
17/05/2022 |
4 |
1012 |
8 551,40 |
|
7 |
1500 |
12 900,00 |
18/05/2022 |
- |
- |
- |
|
9 |
1131 |
10 031,97 |
19/05/2022 |
- |
- |
- |
|
5 |
619 |
5 614,33 |
20/05/2022 |
2 |
251 |
2 233,90 |
|
3 |
500 |
4 500,00 |
23/05/2022 |
3 |
1499 |
13 341,10 |
|
4 |
250 |
2 262,50 |
24/05/2022 |
4 |
275 |
2 420,00 |
|
1 |
500 |
4 450,00 |
25/05/2022 |
- |
- |
- |
|
2 |
400 |
3 560,00 |
26/05/2022 |
1 |
500 |
4 450,00 |
|
3 |
500 |
4 500,00 |
27/05/2022 |
16 |
2488 |
21 645,60 |
|
- |
- |
- |
30/05/2022 |
3 |
1000 |
8 550,00 |
|
1 |
1 |
8,80 |
31/05/2022 |
7 |
750 |
6 435,00 |
|
3 |
849 |
7 386,30 |
01/06/2022 |
- |
- |
- |
|
4 |
500 |
4 300,00 |
02/06/2022 |
9 |
500 |
4 300,00 |
|
2 |
152 |
1 322,40 |
03/06/2022 |
15 |
1200 |
10 224,00 |
|
2 |
149 |
1 296,30 |
06/06/2022 |
3 |
600 |
5 100,00 |
|
1 |
1 |
8,60 |
07/06/2022 |
1 |
1 |
8,51 |
|
3 |
189 |
1 625,40 |
08/06/2022 |
4 |
150 |
1 282,50 |
|
4 |
411 |
3 538,71 |
09/06/2022 |
3 |
655 |
5 619,90 |
|
- |
- |
- |
10/06/2022 |
8 |
845 |
7 233,20 |
|
3 |
500 |
4 350,00 |
13/06/2022 |
21 |
2488 |
20 501,12 |
|
- |
- |
- |
14/06/2022 |
21 |
4100 |
32 267,00 |
|
- |
- |
- |
15/06/2022 |
5 |
1500 |
11 220,00 |
|
- |
- |
- |
16/06/2022 |
10 |
3000 |
21 540,00 |
|
- |
- |
- |
|
Buy Side |
|
Sell Side |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
Total |
1534 |
269698 |
2 044 848,96 |
|
1127 |
202157 |
1 565 786,52 |
17/06/2022 |
3 |
1000 |
7 000,00 |
|
1 |
500 |
3 600,00 |
20/06/2022 |
7 |
1000 |
7 000,00 |
|
3 |
971 |
6 942,65 |
21/06/2022 |
1 |
500 |
3 550,00 |
|
3 |
180 |
1 299,60 |
22/06/2022 |
16 |
4500 |
30 375,00 |
|
1 |
500 |
3 500,00 |
23/06/2022 |
8 |
1000 |
6 650,00 |
|
- |
- |
- |
24/06/2022 |
- |
- |
- |
|
5 |
500 |
3 350,00 |
27/06/2022 |
10 |
2000 |
12 960,00 |
|
4 |
500 |
3 400,00 |
28/06/2022 |
7 |
2500 |
15 325,00 |
|
1 |
1 |
6,50 |
29/06/2022 |
18 |
6000 |
34 260,00 |
|
1 |
500 |
2 950,00 |
30/06/2022 |
- |
- |
- |
|
1 |
4 |
22,80 |
01/07/2022 |
5 |
500 |
2 800,00 |
|
1 |
1 |
5,70 |
04/07/2022 |
- |
- |
- |
|
10 |
3495 |
21 389,40 |
05/07/2022 |
- |
- |
- |
|
6 |
622 |
3 806,64 |
06/07/2022 |
3 |
1000 |
5 950,00 |
|
1 |
1 |
6,25 |
07/07/2022 |
7 |
2500 |
14 400,00 |
|
1 |
1 |
6,00 |
08/07/2022 |
- |
- |
- |
|
3 |
602 |
3 503,64 |
11/07/2022 |
10 |
1486 |
8 470,20 |
|
2 |
398 |
2 348,20 |
13/07/2022 |
3 |
514 |
2 878,40 |
|
- |
- |
- |
14/07/2022 |
3 |
500 |
2 750,00 |
|
2 |
171 |
974,70 |
15/07/2022 |
3 |
501 |
2 705,40 |
|
1 |
1 |
5,44 |
18/07/2022 |
1 |
1 |
5,43 |
|
1 |
1 |
5,43 |
19/07/2022 |
7 |
1501 |
7 805,20 |
|
1 |
1 |
5,33 |
20/07/2022 |
1 |
500 |
2 500,00 |
|
4 |
500 |
2 600,00 |
21/07/2022 |
1 |
500 |
2 450,00 |
|
2 |
149 |
759,90 |
22/07/2022 |
1 |
1 |
4,92 |
|
3 |
352 |
1 795,20 |
26/07/2022 |
3 |
501 |
2 454,90 |
|
1 |
1 |
4,96 |
27/07/2022 |
1 |
1 |
4,91 |
|
1 |
1 |
4,91 |
28/07/2022 |
1 |
500 |
2 450,00 |
|
- |
- |
- |
29/07/2022 |
3 |
1500 |
7 095,00 |
|
1 |
8 |
38,40 |
01/08/2022 |
1 |
500 |
2 350,00 |
|
6 |
492 |
2 361,60 |
02/08/2022 |
- |
- |
- |
|
1 |
1 |
4,80 |
03/08/2022 |
1 |
135 |
621,00 |
|
- |
- |
- |
04/08/2022 |
2 |
365 |
1 679,00 |
|
- |
- |
- |
05/08/2022 |
3 |
501 |
2 304,60 |
|
2 |
44 |
206,80 |
08/08/2022 |
- |
- |
- |
|
7 |
1456 |
6 988,80 |
09/08/2022 |
2 |
1000 |
4 680,00 |
|
3 |
1000 |
4 850,00 |
10/08/2022 |
- |
- |
- |
|
5 |
750 |
3 615,00 |
11/08/2022 |
- |
- |
- |
|
6 |
2500 |
12 600,00 |
|
Buy Side |
|
Sell Side |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
Total |
1534 |
269698 |
2 044 848,96 |
|
1127 |
202157 |
1 565 786,52 |
12/08/2022 |
- |
- |
- |
|
5 |
2000 |
10 540,00 |
15/08/2022 |
1 |
500 |
2 600,00 |
|
2 |
500 |
2 700,00 |
16/08/2022 |
5 |
600 |
3 114,00 |
|
- |
- |
- |
17/08/2022 |
7 |
1600 |
7 984,00 |
|
- |
- |
- |
18/08/2022 |
1 |
1 |
4,96 |
|
1 |
1 |
4,96 |
19/08/2022 |
3 |
1000 |
4 850,00 |
|
2 |
500 |
2 520,00 |
22/08/2022 |
3 |
500 |
2 450,00 |
|
- |
- |
- |
23/08/2022 |
4 |
501 |
2 404,80 |
|
2 |
2 |
9,80 |
24/08/2022 |
3 |
1001 |
4 754,75 |
|
5 |
499 |
2 445,10 |
25/08/2022 |
5 |
500 |
2 350,00 |
|
1 |
500 |
2 400,00 |
26/08/2022 |
3 |
501 |
2 354,70 |
|
1 |
346 |
1 660,80 |
29/08/2022 |
1 |
499 |
2 295,40 |
|
- |
- |
- |
30/08/2022 |
- |
- |
- |
|
7 |
1654 |
8 038,44 |
01/09/2022 |
3 |
1500 |
6 750,00 |
|
2 |
24 |
112,80 |
05/09/2022 |
1 |
500 |
2 190,00 |
|
- |
- |
- |
06/09/2022 |
- |
- |
- |
|
7 |
500 |
2 200,00 |
07/09/2022 |
9 |
1600 |
6 720,00 |
|
1 |
1 |
4,44 |
08/09/2022 |
1 |
1 |
4,16 |
|
2 |
131 |
556,75 |
09/09/2022 |
- |
- |
- |
|
5 |
610 |
2 616,90 |
12/09/2022 |
3 |
500 |
2 100,00 |
|
2 |
10 |
43,00 |
13/09/2022 |
1 |
258 |
1 057,80 |
|
1 |
1 |
4,30 |
14/09/2022 |
3 |
501 |
2 004,00 |
|
1 |
1 |
4,11 |
15/09/2022 |
3 |
751 |
3 056,57 |
|
3 |
1000 |
4 100,00 |
16/09/2022 |
4 |
500 |
2 050,00 |
|
4 |
751 |
3 154,20 |
19/09/2022 |
3 |
749 |
3 010,98 |
|
2 |
500 |
2 150,00 |
21/09/2022 |
6 |
1000 |
4 030,00 |
|
- |
- |
- |
22/09/2022 |
3 |
500 |
2 300,00 |
|
18 |
5474 |
25 837,28 |
23/09/2022 |
12 |
3550 |
15 407,00 |
|
- |
- |
- |
26/09/2022 |
2 |
500 |
2 000,00 |
|
1 |
500 |
2 050,00 |
27/09/2022 |
2 |
750 |
3 000,00 |
|
3 |
250 |
1 012,50 |
28/09/2022 |
5 |
1250 |
4 925,00 |
|
- |
- |
- |
29/09/2022 |
3 |
1500 |
5 700,00 |
|
1 |
2 |
8,00 |
30/09/2022 |
6 |
1500 |
5 475,00 |
|
- |
- |
- |
03/10/2022 |
- |
- |
- |
|
3 |
350 |
1 316,00 |
04/10/2022 |
- |
- |
- |
|
7 |
1000 |
3 880,00 |
05/10/2022 |
4 |
1467 |
5 589,27 |
|
3 |
948 |
3 754,08 |
06/10/2022 |
- |
- |
- |
|
25 |
6500 |
27 365,00 |
07/10/2022 |
1 |
500 |
2 300,00 |
|
23 |
4566 |
21 505,86 |
|
Buy Side |
|
Sell Side |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
Total |
1534 |
269698 |
2 044 848,96 |
|
1127 |
202157 |
1 565 786,52 |
10/10/2022 |
5 |
1000 |
6 350,00 |
|
34 |
10761 |
69 731,28 |
11/10/2022 |
32 |
6500 |
39 975,00 |
|
18 |
4100 |
28 946,00 |
12/10/2022 |
14 |
3000 |
17 250,00 |
|
4 |
1320 |
7 774,80 |
13/10/2022 |
10 |
3000 |
16 140,00 |
|
- |
- |
- |
14/10/2022 |
2 |
500 |
2 800,00 |
|
18 |
4500 |
25 785,00 |
17/10/2022 |
- |
- |
- |
|
26 |
5997 |
38 500,74 |
18/10/2022 |
12 |
3000 |
18 750,00 |
|
5 |
701 |
4 836,90 |
19/10/2022 |
15 |
2500 |
15 100,00 |
|
- |
- |
- |
20/10/2022 |
3 |
501 |
3 056,10 |
|
6 |
2500 |
15 500,00 |
21/10/2022 |
14 |
1499 |
8 994,00 |
|
- |
- |
- |
24/10/2022 |
4 |
1500 |
9 000,00 |
|
5 |
530 |
3 264,80 |
25/10/2022 |
10 |
2100 |
12 096,00 |
|
7 |
770 |
4 604,60 |
26/10/2022 |
- |
- |
- |
|
16 |
2000 |
11 700,00 |
27/10/2022 |
7 |
1000 |
6 050,00 |
|
4 |
1500 |
9 180,00 |
28/10/2022 |
12 |
3001 |
17 765,92 |
|
3 |
501 |
3 056,10 |
31/10/2022 |
51 |
13500 |
68 580,00 |
|
- |
- |
- |
01/11/2022 |
2 |
500 |
2 325,00 |
|
2 |
500 |
2 400,00 |
03/11/2022 |
8 |
3650 |
16 498,00 |
|
- |
- |
- |
04/11/2022 |
6 |
1000 |
4 500,00 |
|
1 |
500 |
2 300,00 |
07/11/2022 |
9 |
1800 |
7 884,00 |
|
- |
- |
- |
08/11/2022 |
7 |
1500 |
6 390,00 |
|
2 |
750 |
3 240,00 |
09/11/2022 |
4 |
1000 |
4 330,00 |
|
- |
- |
- |
10/11/2022 |
13 |
1700 |
7 021,00 |
|
3 |
1000 |
4 180,00 |
11/11/2022 |
- |
- |
- |
|
5 |
990 |
4 257,00 |
14/11/2022 |
- |
- |
- |
|
9 |
2110 |
9 537,20 |
15/11/2022 |
15 |
2851 |
12 401,85 |
|
1 |
1 |
4,49 |
16/11/2022 |
7 |
1000 |
4 250,00 |
|
1 |
250 |
1 070,00 |
17/11/2022 |
4 |
500 |
2 150,00 |
|
4 |
1250 |
5 437,50 |
18/11/2022 |
8 |
1351 |
5 741,75 |
|
3 |
401 |
1 724,30 |
21/11/2022 |
5 |
1000 |
4 150,00 |
|
- |
- |
- |
22/11/2022 |
10 |
1750 |
7 017,50 |
|
1 |
500 |
2 100,00 |
23/11/2022 |
3 |
1500 |
5 955,00 |
|
4 |
750 |
3 015,00 |
24/11/2022 |
- |
- |
- |
|
1 |
500 |
2 000,00 |
25/11/2022 |
4 |
1000 |
4 000,00 |
|
3 |
750 |
3 015,00 |
28/11/2022 |
2 |
500 |
2 000,00 |
|
8 |
1000 |
4 080,00 |
29/11/2022 |
3 |
750 |
3 240,00 |
|
17 |
3750 |
16 425,00 |
30/11/2022 |
3 |
1000 |
4 250,00 |
|
- |
- |
- |
17/11/2022 |
4 |
500 |
2 150,00 |
|
4 |
1250 |
5 437,50 |
|
Buy Side |
|
Sell Side |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
Total |
1534 |
269698 |
2 044 848,96 |
|
1127 |
202157 |
1 565 786,52 |
18/11/2022 |
8 |
1351 |
5 741,75 |
|
3 |
401 |
1 724,30 |
21/11/2022 |
5 |
1000 |
4 150,00 |
|
- |
- |
- |
22/11/2022 |
10 |
1750 |
7 017,50 |
|
1 |
500 |
2 100,00 |
23/11/2022 |
3 |
1500 |
5 955,00 |
|
4 |
750 |
3 015,00 |
24/11/2022 |
- |
- |
- |
|
1 |
500 |
2 000,00 |
25/11/2022 |
4 |
1000 |
4 000,00 |
|
3 |
750 |
3 015,00 |
28/11/2022 |
2 |
500 |
2 000,00 |
|
8 |
1000 |
4 080,00 |
29/11/2022 |
3 |
750 |
3 240,00 |
|
17 |
3750 |
16 425,00 |
30/11/2022 |
3 |
1000 |
4 250,00 |
|
- |
- |
- |
05/12/2022 |
- |
- |
- |
|
3 |
598 |
2 583,36 |
06/12/2022 |
4 |
701 |
3 007,29 |
|
6 |
701 |
3 021,31 |
07/12/2022 |
12 |
1750 |
7 367,50 |
|
- |
- |
- |
08/12/2022 |
4 |
751 |
3 094,12 |
|
1 |
1 |
4,18 |
09/12/2022 |
1 |
1 |
4,09 |
|
2 |
40 |
166,00 |
12/12/2022 |
6 |
850 |
3 468,00 |
|
1 |
1 |
4,15 |
13/12/2022 |
1 |
1 |
4,07 |
|
6 |
1211 |
5 025,65 |
14/12/2022 |
- |
- |
- |
|
3 |
258 |
1 083,60 |
15/12/2022 |
11 |
1001 |
4 104,10 |
|
1 |
1 |
4,18 |
16/12/2022 |
3 |
251 |
1 016,55 |
|
2 |
201 |
818,07 |
19/12/2022 |
4 |
255 |
1 032,75 |
|
15 |
3944 |
16 880,32 |
20/12/2022 |
8 |
750 |
3 232,50 |
|
1 |
180 |
783,00 |
21/12/2022 |
2 |
500 |
2 150,00 |
|
3 |
250 |
1 080,00 |
22/12/2022 |
2 |
1000 |
4 280,00 |
|
10 |
1250 |
5 462,50 |
23/12/2022 |
1 |
1 |
4,40 |
|
7 |
1501 |
6 679,45 |
28/12/2022 |
3 |
501 |
2 204,40 |
|
1 |
1 |
4,44 |
29/12/2022 |
- |
- |
- |
|
7 |
2000 |
8 980,00 |
30/12/2022 |
2 |
500 |
2 235,00 |
|
- |
- |
- |
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with NASH,
mucopolysaccharidoses (MPS) and other diseases with significant
unmet medical needs. The Company benefits from a strong expertise
and experience in the domain of compounds targeting nuclear
receptors, transcription factors and epigenetic modulation.
Inventiva is currently advancing one clinical candidate, has a
pipeline of two preclinical programs and continues to explore other
development opportunities to add to its pipeline.
Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with NASH, a common and
progressive chronic liver disease for which there are currently no
approved therapies. In 2020, Inventiva reported positive results
from its Phase IIb clinical trial evaluating lanifibranor for the
treatment of patients with NASH and received Breakthrough Therapy
and Fast Track status from the U.S. Food and Drug Administration
(“FDA”) for lanifibranor in the treatment of NASH.
Inventiva’s pipeline also includes odiparcil, a
drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is in the
process of selecting an oncology development candidate for its
Hippo signaling pathway program.
The Company has a scientific team of
approximately 80 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com.
Contacts
Inventiva Pascaline Clerc VP of Global External
Affairs media@inventivapharma.com +1 240 620
9175 |
Brunswick Group Tristan Roquet Montegon / Aude
Lepreux / Matthieu Benoist Media relations
inventiva@brunswickgroup.com +33 1 53 96 83 83 |
Westwicke, an ICR Company Patricia L. Bank
Investor relations patti.bank@westwicke.com
+1 415 513-1284 |
|
|
|
|
|
|
Important Notice
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release are forward-looking statements. These statements include,
but are not limited to, expectations with respect to the pivotal
Phase III clinical trial evaluating lanifibranor in patients with
NASH, including recruitment of patients for that trial, the
Company’s ability to satisfy conditions precedent to draw down on
the second tranche under the EIB facility, potential future
financings or strategic transactions, milestone payments and
royalties, the Company’s ability to exercise its rights under the
EIB facility, including its call right and right of first refusal,
expectations with respect to EIB’s rights under the EIB facility
and EIB’s potential exercise of warrants, the expected use of
proceeds from the EIB facility, and the sufficiency of Inventiva’s
cash resources and cash runway. Certain of these statements,
forecasts and estimates can be recognized by the use of words such
as, without limitation, “believes”, “anticipates”, “expects”,
“intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”,
“could”, “might”, “should”, and “continue” and similar expressions.
Such statements are not historical facts but rather are statements
of future expectations and other forward-looking statements that
are based on management's beliefs. These statements reflect such
views and assumptions prevailing as of the date of the statements
and involve known and unknown risks and uncertainties that could
cause future results, performance or future events to differ
materially from those expressed or implied in such statements.
Future events are difficult to predict and may depend upon factors
that are beyond Inventiva's control. There can be no guarantees
with respect to pipeline product candidates that the clinical trial
results will be available on their anticipated timeline, that
future clinical trials will be initiated as anticipated, that
product candidates will receive the necessary regulatory approvals.
Actual results may turn out to be materially different from the
anticipated future results, performance or achievements expressed
or implied by such statements, forecasts and estimates, due to a
number of factors, including that Inventiva is a clinical-stage
company with no approved products and no historical product
revenues, Inventiva has incurred significant losses since
inception, Inventiva has a limited operating history and has never
generated any revenue from product sales, Inventiva will require
additional capital to finance its operations, Inventiva's future
success is dependent on the successful clinical development,
regulatory approval and subsequent commercialization of current and
any future product candidates, preclinical studies or earlier
clinical trials are not necessarily predictive of future results
and the results of Inventiva's clinical trials may not support
Inventiva's product candidate claims, Inventiva may encounter
substantial delays in its clinical trials or Inventiva may fail to
demonstrate safety and efficacy to the satisfaction of applicable
regulatory authorities, enrolment and retention of patients in
clinical trials is an expensive and time-consuming process and
could be made more difficult or rendered impossible by multiple
factors outside Inventiva's control, Inventiva's product candidates
may cause adverse drug reactions or have other properties that
could delay or prevent their regulatory approval, or limit their
commercial potential, Inventiva faces substantial competition and
Inventiva’s business, and preclinical studies and clinical
development programs and timelines, its financial condition and
results of operations could be materially and adversely affected by
the current COVID-19 pandemic and geopolitical events, such as the
conflict between Russia and Ukraine, related sanctions and related
impacts and potential impacts on the initiation, enrolment and
completion of Inventiva’s clinical trials on anticipated timelines
and macroeconomic conditions, including global inflation and
uncertain financial markets or at all. Given these risks and
uncertainties, no representations are made as to the accuracy or
fairness of such forward-looking statements, forecasts and
estimates. Furthermore, forward-looking statements, forecasts and
estimates only speak as of the date of this press release. Readers
are cautioned not to place undue reliance on any of these
forward-looking statements.
Please refer to the Universal Registration
Document for the year ended December 31, 2021 filed with the
Autorité des Marchés Financiers on March 11, 2022, the Annual
Report on Form 20-F for the year ended December 31, 2021 filed with
the Securities and Exchange Commission on March 11, 2022 and the
financial report for the first half of 2022 filed with the
Securities and Exchange Commission on September 22, 2022 for
additional information in relation to such factors, risks and
uncertainties.
All information in this press release is as of
the date of the release. Except as required by law, Inventiva has
no intention and is under no obligation to update or review the
forward-looking statements referred to above.
- Inventiva - PR - Liquidity contract - H2 22 - EN - 01 30
2023
Inventiva (EU:IVA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Inventiva (EU:IVA)
Historical Stock Chart
From Oct 2023 to Oct 2024